LENZ Therapeutics (LENZ) Profit After Tax (2020 - 2026)

LENZ Therapeutics (LENZ) has 7 years of Profit After Tax data on file, last reported at -$41.5 million in Q1 2026.

• On a quarterly basis, Profit After Tax fell 183.8% year-over-year to -$41.5 million in Q1 2026; TTM through Mar 2026 was -$108.8 million, a 128.14% decrease from a year earlier, with the FY2025 full-year figure at -$82.1 million, down 64.92% from the prior year.
• Profit After Tax for Q1 2026 stood at -$41.5 million, down from -$35.8 million in the prior quarter.
• Over the last five years, Profit After Tax for LENZ reached as high as -$9.6 million in Q3 2024 and fell as low as -$41.5 million in Q1 2026.
• Historically, Profit After Tax has averaged -$20.2 million across 5 years, with a median of -$16.6 million in 2024.
• Across the five-year window, Profit After Tax surged 50.96% in 2023 and sank 183.8% in 2026, its largest moves.
• Year by year, Profit After Tax stood at -$24.1 million in 2022, then increased by 1.51% to -$23.7 million in 2023, then soared by 44.4% to -$13.2 million in 2024, then plunged by 172.23% to -$35.8 million in 2025, then retreated by 15.73% to -$41.5 million in 2026.
• Per Business Quant data, the three most recent Profit After Tax figures were -$41.5 million in Q1 2026, -$35.8 million in Q4 2025, and -$16.5 million in Q3 2025.